Function associated transforming growth factor-β gene polymorphism in chronic beryllium disease
- 5 March 2005
- journal article
- research article
- Published by Springer Nature in Journal of Molecular Medicine
- Vol. 83 (5) , 397-405
- https://doi.org/10.1007/s00109-004-0626-0
Abstract
Chronic beryllium disease (CBD) is a rare occupational, granulomatous lung disease clinically resembling sarcoidosis. The immune response to beryllium is thought to depend on genetic susceptibility. Although a glutamic acid in position 69 of the human leukocyte antigen-DP β chain (HLA-DPB1-Glu69) is associated with the development of CBD, it cannot fully explain susceptibility. It is likely that additionally other genes are involved in regulating the immune and inflammatory response in the pathogenesis of this disease. Functional gene polymorphisms (PMs) of the tumor necrosis factor (TNF)A and transforming growth factor (TGF) β1 genes are suspected to modify the course of granulomatous disorders. We analyzed the TGF-β1 (codon 25) PM in 59 patients with CBD and 164 matched healthy controls, from two groups of European/Israeli and United States origin. Additionally, patients were genotyped for HLA class II gene variants and the TNFA (−308) PM. The most significant results were found for the TGF-β1 (codon 25) PM with a shift towards the low producing non-GG genotypes in the subgroup of European and Israeli patients with CBD (62.50% vs. 13.82% in healthy controls; P1 (codon 25) PM genotype frequencies from United States CBD patients differed significantly from those of European and Israeli patients. In contrast, increased frequencies for the high producing TNFA2 allele were found only in the patients from the United States (28.20% vs. 8.96% in healthy controls; P1 (codon 25) PM genotype frequency associated with a low TGF-β release suggests that immunoregulatory cytokines such as TGF-β are involved in the pathogenesis of CBD. Moreover, based on the interaction of gene PMs associated with the control of the immune response, such as TNF-α and TGF-β1, with a specific immune response gene such as HLA-DPB1-Glu69 or other HLA-class II PMs driving the immune response to Be, the present data suggest that a combination of different genetic backgrounds determine susceptibility for the same immunopathological reaction and disease.Keywords
This publication has 31 references indexed in Scilit:
- HLA-DP-unrestricted TNF-α release in beryllium-stimulated peripheral blood mononuclear cellsEuropean Respiratory Journal, 2002
- Major histocompatibility locus genetic markers of beryllium sensitization and diseaseEuropean Respiratory Journal, 2001
- Beryllium binding to HLA-DP molecule carrying the marker of susceptibility to berylliosis glutamate β69Human Immunology, 2001
- POLYMORPHISMS AT POSITION −308 IN THE PROMOTER REGION OF THE TNF-α AND IN THE FIRST INTRON OF THE TNF-β GENES AND SPONTANEOUS AND LIPOPOLYSACCHARIDE-INDUCED TNF-α RELEASE IN SARCOIDOSISCytokine, 1999
- TGF-β 1 DNA Polymorphisms, Protein Levels, and Blood PressureHypertension, 1999
- TUMOUR NECROSIS FACTOR ALPHA PROMOTER GENE POLYMORPHISM IN SARCOIDOSISCytokine, 1997
- Interaction of genetic and exposure factors in the prevalence of berylliosisAmerican Journal of Industrial Medicine, 1997
- A genomic polymorphism within the tumor necrosis factor locus influences plasma tumor necrosis factor-alpha concentrations and outcome of patients with severe sepsisCritical Care Medicine, 1996
- HLA-DPB1 Glutamate 69: a Genetic Marker of Beryllium DiseaseScience, 1993
- Blood Cell Proliferation Response to Beryllium: Analysis by Receiver-Operating CharacteristicsJournal of Occupational and Environmental Medicine, 1991